logo-loader
RNS
Oxford BioDynamics PLC

Board Appointment

RNS Number : 3067S
Oxford BioDynamics PLC
27 August 2026
 

27 August 2026                                        

 

Oxford BioDynamics Plc

 

("OBD" or the "Company")

 

Board Appointment

 

Oxford, UK - 27 August 2026 - Oxford BioDynamics Plc (AIM: OBD), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based 3D genomics platform for pharma and biotech partners, today announces the appointment of Richard Compton, Chief Executive Officer, to the Board as an Executive Director with immediate effect. The appointment follows the Company's announcement of 30 June 2026 regarding Mr Compton's appointment as Chief Executive Officer and the completion of regulatory due diligence by the Company's Nomad.

 

Iain Ross, Non-Executive Chairman of Oxford BioDynamics, said:  

 

"I am delighted to welcome Richard to the Board of OBD. In the short time he has been with the Company as CEO he has proven he has the qualities and experience to lead the team to commercial success. With the support of the shareholders I believe he will be able to realise the success for which we have all been striving."

 

The following disclosures are provided in respect of Richard Alan Compton, aged 56, pursuant to Schedule 2(g) of the AIM Rules for Companies.

 

Mr Compton holds 300,000,000 ordinary shares in the capital of the Company, representing 2.2% of the Company's ordinary share capital.

 

Current Directorships / Partnerships

Previous Directorships / Partnerships

(Last 5 years)

Compton Advisory Ltd (Company No. 16851684)

None.

 

 

For further information please contact:

 

Oxford BioDynamics Plc

Iain Ross, Non-Executive Chairman

Richard Compton, CEO

Paul Stockdale, CFO

 

+44 (0)1865 518910

Singer Capital Markets - Nominated Adviser and Broker

Alex Bond / Russell Cook / Anastassiya Eley

 

 

+44 (0)20 7496 3000

OAK Securities - Joint Broker

Matthew Clarke / Jerry Keen

 

 

+44 (0)20 3973 3678

Camarco - Financial PR

Marc Cohen / Sukaina Virji / Tilly Butcher / Fergus Young

 

+44 (0)20 3757 4980

OBDFinancial@camarco.co.uk

 

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch Orion, a cloud-based 3D genomics platform that transforms existing datasets into actionable insights for pharma and biotech partners.

Currently OBD has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch, which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

The Company's recently launched proprietary AI predictive platform, EpiSwitch® Orion, makes the Company's knowledgebase and analytical tools available to researchers and partners, allowing them to generate insights into 3D regulatory biology from existing datasets. EpiSwitch Orion is a cloud-based 3D genomics platform that enables pharmaceutical partners to transform standard sequencing data - including legacy whole genome datasets - into actionable discovery insights in hours rather than months. By revealing the genome's 3D architecture, EpiSwitch Orion illuminates the 90-95% of disease-associated variants in non-coding regions that traditional NGS and GWAS approaches cannot decipher, bridging the gap between statistical associations and druggable therapeutic targets. The platform is supported by the world's largest curated 3D genomics knowledgebase, featuring over 1.5 billion data points and 15 million high-confidence genomic connections validated across 18,000+ patient samples in more than 40 diseases - a foundation built over nearly two decades that enables partners to identify targets, build predictive classifier models, and design precision interventions at unprecedented speed. 

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

Since inception, the Company has participated in more than 40 collaborations with pharmaceutical and academic partners, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma America, and has been awarded funding through the US Foundation for the National Institutes of Health's Partnership for Accelerating Cancer Therapies programme and the EU-funded HIPPOCRATES consortium in psoriatic arthritis.

The Company's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAZQLFLQVLZBBE
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Oxford BioDynamics' Bartu Ahiska on breakthrough CFS test

Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) senior director of commercial development & marketing comms, Bartu Ahiska, talked with Proactive's Stephen Gunnion about the company’s breakthrough diagnostic blood test for chronic fatigue syndrome (CFS), also known as ME. Ahiska said this was...

on 10/13/2025

5 min read